Christopher Haqq
Chief Tech/Sci/R&D Officer presso ELICIO THERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Christopher M.
Haqq is currently the Chief Medical Officer & Executive Vice President at Elicio Therapeutics, Inc. (United States) and the Chief Medical Officer, EVP & Head-Research at Elicio Therapeutics, Inc. He previously held positions as an Independent Director at Consonance-HFW Acquisition Corp., Manager-Early Development Oncology Group at Amgen, Inc., Vice President-Clinical Research & Development at Cougar Biotechnology, Inc., Assistant Professor at The University of California, San Francisco, Vice President-Clinical Research & Development at Janssen Oncology, Inc., and Chief Scientific Officer, Executive VP-R&D at Atara Biotherapeutics, Inc. Dr. Haqq received his undergraduate degree from Stanford University and his doctorate from Harvard Medical School.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ELICIO THERAPEUTICS, INC
-.--% | 01/02/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Christopher Haqq
| Società | Posizione | Inizio |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/10/2019 |
Elicio Therapeutics, Inc. (Old)
 Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01/10/2019 |
Precedenti posizioni note di Christopher Haqq
| Società | Posizione | Fine |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 25/10/2019 |
Janssen Oncology, Inc.
 Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Janssen Oncology, Inc. engages in the development of pharmaceutical products for the treatment of cancer. It conducts pharmaceutical product trials. The company is headquartered in Los Angeles, CA. | Chief Tech/Sci/R&D Officer | 01/09/2011 |
Cougar Biotechnology, Inc. /Old/
 Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA. | Chief Tech/Sci/R&D Officer | 13/07/2009 |
| SURROZEN, INC. | Director/Board Member | - |
| The University of California, San Francisco | Corporate Officer/Principal | - |
Formazione di Christopher Haqq
| Stanford University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| ELICIO THERAPEUTICS, INC. | Health Technology |
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Cougar Biotechnology, Inc. /Old/
Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA. | Health Technology |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Health Technology |
Consonance-HFW Acquisition Corp.
 Consonance-HFW Acquisition Corp. Financial ConglomeratesFinance Consonance-HFW Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisitions, share purchase, reorganization, or similar business combination. The company was founded by Gad Soffer and Kevin Harold Livingston on August 21, 2020 and is headquartered in Princeton, NJ. | Finance |
Janssen Oncology, Inc.
Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Janssen Oncology, Inc. engages in the development of pharmaceutical products for the treatment of cancer. It conducts pharmaceutical product trials. The company is headquartered in Los Angeles, CA. | Health Technology |
- Borsa valori
- Insiders
- Christopher Haqq
